DSIP (Delta Sleep-Inducing Peptide): Research Guide

DSIP is a nonapeptide (nine amino acids: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated in 1977 by Schoenenberger and Monnier from the cerebral venous blood of rabbits during electrically induced sleep, using a cross-circulation technique — dialysed blood from sleeping rabbits was infused into awake recipient rabbits, which then showed increased delta and spindle EEG activity characteristic of slow-wave sleep. The peptide's amino acid sequence was formally published the following year. It has since been detected endogenously in human plasma and cerebrospinal fluid as well.

DSIP's mechanism is the least settled part of its research history. Unlike most peptides in this research library, no specific cell-surface receptor for DSIP has been conclusively identified in the published literature, despite nearly five decades of study.

HPA-Axis Neuromodulation

Published research characterises DSIP as a neuromodulator within the hypothalamic-pituitary-adrenal (HPA) axis, with proposed anxiolytic and stress-attenuating effects distinct from its sleep-related activity.

Opioid Receptor Interaction

Some published work reports DSIP interacting with opioid receptor systems, which has been proposed as a partial explanation for its reported effects on pain perception and stress response — though this is one proposed mechanistic thread among several, not a settled, singular mechanism of action.

The Unresolved Receptor Question

Worth stating plainly: DSIP's name describes an observed effect (delta-wave sleep induction in the original rabbit experiments), not a confirmed mechanism. Decades of follow-up research have proposed several mechanistic threads — HPA-axis modulation, opioid system interaction, antioxidant enzyme upregulation — without converging on a single, confirmed receptor-level explanation. This is different from most compounds in this research library, where a primary receptor or pathway is well characterised even if downstream effects are still being mapped.

Early Human Sleep Studies

An early controlled study in normal volunteers administered DSIP via slow intravenous infusion (25 nmol/kg) and reported total sleep time increased by a median of 59% within a 130-minute interval following treatment, compared to placebo (Schneider-Helmert et al., 1981). Delayed effects on subsequent-night sleep included shorter sleep onset and improved sleep efficiency.

The Slow-Wave Sleep Question — A Genuine Discrepancy

This is where the evidence is more mixed than DSIP's name implies. A separate controlled study specifically examining chronic insomniac patients found that stage 1 sleep, slow-wave sleep (stages 3 and 4), and REM sleep were not significantly modified by DSIP administration — the measured sleep improvements were instead attributed to increases in stage 2 sleep (Monti et al., 1987). This directly complicates the "delta sleep-inducing" framing for the specific patient population most likely to seek out sleep-focused research: the peptide's own namesake effect was not reproduced in this particular trial population.

Open-Label and Clinical Trial Data

An open-label study of seven patients with severe insomnia, treated with a series of ten DSIP injections, reported sleep normalised in six of seven cases for follow-up periods of three to seven months (Kaeser, 1984). Against this, other published assessments concluded that DSIP's sleep-improvement effect was of limited clinical significance overall. Read together, the human trial record supports a real but modest and inconsistent effect — not the clean, uniformly positive picture that "delta sleep-inducing peptide" as a name might suggest.

Pharmaceutical Development History

Pharmaceutical interest in DSIP peaked through the 1980s and 1990s, with clinical trials conducted across insomnia, depression, and stress-related conditions. Development did not progress to regulatory approval, and active pharmaceutical interest had largely stopped by the early 2000s.

DSIP has never been submitted for regulatory approval in any jurisdiction. No FDA, EMA, or MOHAP approval exists for DSIP under any indication. It circulates exclusively as a research-grade peptide, not as an approved pharmaceutical product.

• A confirmed receptor or primary mechanism — despite nearly 50 years of research, no single receptor-level explanation for DSIP's reported effects has been established
• Consistent slow-wave sleep effects in humans — published findings are genuinely mixed, with at least one controlled study in the relevant patient population (chronic insomniacs) finding no significant change in stages 3/4 sleep specifically
• Clinical significance — published assessments disagree on whether DSIP's measured sleep effects are meaningful at a clinical level
• Optimal research parameters are not established in any standardised published protocol
• Long-term effects are not characterised in the published literature

DSIP is available as a lyophilised powder for research applications, requiring reconstitution with bacteriostatic water before use in any research protocol. See the reconstitution guide → for the full process, the storage guide → for compound-specific shelf-life data, and the bacteriostatic water guide → for what the reconstitution vehicle itself is and how to verify its quality.